One Turn Open the globe →

The story so far · 2 days, November 10 to 11, 2026

FDA orders eye-risk warnings on GLP-1 drugs

One Turn followed this story across 2 editions, from Silver Spring, United States on November 10, 2026. Newest first.

These drugs are sold under brands such as Ozempic and Mounjaro.

Open the latest on the 3D globe →

Day by day

  1. FDA adds eye risk warning to GLP-1 drugs
  2. FDA orders eye-risk warnings on GLP-1 drugs

Every installment

Wednesday, November 11, 2026 · Day 2 · Health · Silver Spring, Maryland · United States of America

FDA orders eye-risk warnings on GLP-1 drugs

The FDA told makers of semaglutide and tirzepatide to warn about a rare optic nerve disorder that can cause permanent vision loss.

Why it matters: Millions use these drugs for diabetes and weight loss.

Sources: BBC News via Wikipedia · See it on the globe

Tuesday, November 10, 2026 · Day 1 · Health · Silver Spring, United States · United States of America

FDA adds eye risk warning to GLP-1 drugs

The FDA ordered makers of Ozempic, Wegovy and similar drugs to add warnings about NAION, a rare optic nerve condition that can cause blindness.

Why it matters: Millions use these drugs and should know the risk.

Sources: CNBC, BBC News, BBC News via Wikipedia · See it on the globe

Where

More running stories →